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In their recent Matters Arising, Scurr 
et al. (2010) questioned several of 
our conclusions regarding the role 
of IGFBP7 in BRAFV600E-mediated 
senescence induction. In our original 
study in Cell (Wajapeyee et al., 2008), 
we used a genome-wide RNA inter-
ference (RNAi) screen to identify 17 
genes required for an activated BRAF 
oncogene (BRAFV600E) to block pro-
liferation of primary melanocytes and 
melanoma cells. One of these genes 
encodes a secreted protein, IGFBP7, 
which we showed has a central role in 
BRAFV600E-mediated senescence and 
apoptosis. Here, we reproduce several 
of the key findings of our earlier study 
and present new results that substanti-
ate our original claims.
In our original study (Wajapeyee et 
al., 2008), we showed that expression 
of BRAFV600E in primary melanocytes 
increases synthesis and secretion of 
IGFBP7, which then acts through an auto-
crine/paracrine pathway to induce senes-
cence. BRAFV600E-mediated induction 
of IGFBP7 expression was directly dem-
onstrated in six independent experiments. 
By contrast, Scurr et al. (2010) claim in 
their Matters Arising that BRAFV600E 
results in decreased IGFBP7. We intro-
duced BRAFV600E into cultured human 
melanocytes by retroviral transduction, 
and in a series of new experiments now 
also show that transient transfection of a 
BRAFV600E-expression plasmid results 
in increased IGFBP7 (Figure S1A available 
online). Furthermore, BRAFV600E-medi-
ated induction of IGFBP7 is, as expected, 
lost following addition of the MEK inhibi-
tor U0126, which blocks BRAF-MEK-ERK 
signaling. Transfection of a BRAFV600E-
expression plasmid into melanocytes also 
induces expression of a cotransfected 
IGFBP7 reporter plasmid (Figure S1B).
Originally, we showed that BRAFV600E 
transcriptionally activates other genes 
involved in senescence or apopto-
sis, including PEA15, SMARCB1, and 
BNIP3L (Wajapeyee et al., 2008). By 
contrast, Scurr et al. (2010) claim that 
following introduction of BRAFV600E 
into primary melanocytes, PEA15, 
SMARCB1, BNIP3L, and p53 protein 
levels are reduced. Their p53 result is 
particularly surprising because acti-
vated oncogenes induce a DNA-damage 
response, which is expected to elevate 
p53 levels. Indeed, in direct contrast to 
Scurr et al. (2010), another study has 
shown that BRAFV600E increases p53 
levels in melanocytes (Yu et al., 2009). To 
confirm our original conclusions, we per-
formed a new immunoblot experiment, 
which shows that BRAFV600E activates 
the DNA-damage response and mark-
edly upregulates expression of PEA15, 
SMARCB1, BNIP3L, and p53 in primary 
melanocytes (Figure S1C).
Following the primary screen, we per-
formed 11 independent experiments 
demonstrating that the BRAFV600E-
mediated block to cellular proliferation 
requires IGFBP7 (Wajapeyee et al., 2008). 
These experiments involved two differ-
ent cell types, two unrelated IGFBP7 
short-hairpin RNAs (shRNAs), and five 
different assays related to cellular prolif-
eration. Finally, we showed that addition 
of IGFBP7 to melanocytes is sufficient to 
induce senescence.
In their Matters Arising, Scurr et al. (2010) 
performed RNAi experiments and did not 
find a role for IGFBP7 in BRAFV600E-
mediated senescence. To investigate this 
discrepancy, we repeated several of our 
original experiments (Wajapeyee et al., 
2008), which confirmed that senescence 
in melanocytes is substantially reduced 
following shRNA-mediated knockdown 
of IGFBP7 (Figures S1D and S1E).
Scurr et al. (2010) suggested that 
our use of drug selection to introduce 
BRAFV600E and shRNAs may have 
inadvertently selected for senescence-
resistant cells. To address this con-
cern, we transduced melanocytes with 
the BRAFV600E-expressing retrovi-
rus in the absence of drug selection. 
IGFBP7 knockdown was performed 
using two unrelated small-interfering 
RNAs (siRNAs) in the absence of drug 
selection, and induction of p16INK4a was 
analyzed as a marker of senescence. 
As expected, BRAFV600E results in 
enhanced expression of p16INK4a as 
well as IGFBP7 (Figure S1F). Moreover, 
the two IGFBP7 siRNAs substantially 
reduced IGFBP7 levels resulting in loss 
of p16INK4a induction.
Although we do not understand the 
failure of Scurr et al. (2010) to observe a 
requirement for IGFBP7 in the induction 
of senescence by the BRAF oncogene, 
it is clear that the populations of cells in 
which senescence is being analyzed are 
markedly different in the two studies. We 
analyzed senescence in BRAFV600E-
expressing cells that contain elevated 
levels of IGFBP7, PEA15, SMARCB1, 
BNIP3L, and p53; by contrast, in Scurr 
et al. (2010) the cells analyzed for senes-
cence contained reduced levels of these 
factors.
Finally, the inability of Scurr et al. 
(2010) to observe a requirement for 
IGFBP7 is essentially a negative result; 
none of the experiments presented 
in Figure 4 of their Matters Arising 
included as a positive control an shRNA 
that knocks down a gene required for 
senescence induction. Scurr et al. 
(2010) presented elsewhere an experi-
ment purporting to show that knock-
down of both p53 and pRb abrogates 
BRAFV600E-mediated senescence 
(Figure S2). However, examination of 
their results reveals that the level of 
BRAFV600E is substantially lower in 
the p53, pRb double-knockdown cells 
than in the control cells, which could 
account for the apparent difference in 
senescence induction.
In our original study (Wajapeyee 
et al., 2008), we showed by immuno-
histochemical analysis that IGFBP7 
expression is lost at high frequency 
in primary melanoma cells containing 
BRAFV600E. Subsequently, we showed 
that in metastatic melanomas IGFBP7 
is lost at an even higher frequency and 
is independent of BRAF mutational 
status (Wajapeyee et al., 2009). Scurr 
et al. (2010) analyzed IGFBP7 expres-
sion in human metastatic, but not pri-
mary, melanoma samples and failed to 
observe a correlation with the status of 
BRAF, which is in agreement with our 
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metastatic melanoma results. To pro-
vide additional support for our origi-
nal conclusions, we analyzed 14 new 
primary melanomas and found that 
IGFBP7 is expressed in all six primary 
melanomas containing wild-type BRAF 
but not in any of eight primary mela-
nomas containing BRAFV600E (Figure 
S1G). As in our previous studies, we 
also provide independent support for 
the immunohistochemical results using 
bisulfite sequencing to determine the 
methylation status of the IGFBP7 pro-
moter (Figure S1H).
Scurr et al. (2010) found that IGFBP7 
is expressed in virtually all BRAFV600E-
containing benign melanocytic lesions 
(nevi), in agreement with our original 
immunohistochemical analysis (Wajap-
eyee et al., 2008). Using tissue arrays, 
Scurr et al. (2010) also found that IGFBP7 
expression is not detectable in ?50% or 
more of the metastatic melanoma sam-
ples containing BRAFV600E or wild-type 
BRAF. The Figure 3B legend in the Scurr 
et al. (2010) Matters Arising states that 
the median expression value for IGFBP7 
is zero for both BRAFV600E-containing 
and wild-type BRAF-containing meta-
static melanoma samples, which is in 
excellent agreement with our immuno-
histochemistry results (Wajapeyee et 
al., 2009). In summary, both our results 
and those of Scurr et al. (2010) show that 
IGFBP7 is expressed in primary melano-
cytes and benign nevi, and that IGFBP7 
expression is lost in a high percentage 
of both BRAFV600E-containing and 
wild-type BRAF-containing metastatic 
 melanomas.
In our original study in Cell, we found that 
loss of IGFBP7 expression correlates with 
the presence of the BRAFV600E mutation 
in human melanoma cell lines (Wajap-
eyee et al., 2008). Scurr et al. (2010) also 
observed frequent loss of IGFBP7 expres-
sion in human cancer cell lines but without 
a correlation with BRAF status. However, 
whereas we analyzed only human mela-
noma cell lines, Scurr et al. (2010) ana-
lyzed a diverse collection of melanoma 
and non-melanoma cell lines as well as 
primary cells. For example, of the 10 cell 
types containing wild-type BRAF and 
another oncogene RAS analyzed by Scurr 
et al. (2010), only one (NM138) is a human 
melanoma cell line. The focus of our origi-
nal study was melanoma and not other 
cancers, and thus the results of Scurr et 
al. (2010) using non-melanoma cell lines 
are not directly relevant to our study or its 
conclusions. Notably, however, two other 
laboratories have found, analogous to our 
results in melanoma, that in primary col-
orectal cancers there is a loss of IGFBP7 
expression that correlates with the pres-
ence of an activating BRAF mutation 
(Hinoue et al., 2009; Suzuki et al., 2010).
In summary, here we provide new 
results confirming several of the main 
conclusions of our original study in Cell 
(Wajapeyee et al., 2008), including (1) 
the transcriptional induction of IGFBP7 
by BRAFV600E, (2) the requirement 
of IGFBP7 for BRAFV600E-mediated 
senescence, and (3) the frequent loss of 
IGFBP7 expression in BRAFV600E-con-
taining primary melanomas. Collectively, 
these results implicate IGFBP7 as a tumor 
suppressor protein in melanomas.
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